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Background: The validity of the surveys on self-reported smoking status is often questioned because smokers 
underestimate cigarette use and deny the habit. It has been suggested that self-report should be accompanied by 
cotinine test. This report evaluates the usefulness of serum cotinine test to assess the association between smok-
ing and periodontal status in a study with a large sample population to be used in studies with other serum markers 
in epidemiologic and periodontal medicine researches.
Material and Methods: 578 patients who were part of a multicenter study on blood biomarkers were evaluated 
about smoking and its relation to periodontal disease. Severity of periodontal disease was determinate using clini-
cal attachment loss (CAL). Smoking was assessed by a questionnaire and a blood sample drawn for serum cotinine 
determination.
Results: The optimal cut-off point for serum cotinine was 10 ng/ml. Serum cotinine showed greater association 
with severity of CAL than self-report for mild-moderate CAL [OR 2.03 (CI95% 1.16-3.53) vs. OR 1.08 (CI95% 
0.62-1.87) ] advanced periodontitis  [OR 2.36 (CI95% 1.30- 4.31) vs. OR 2.06 (CI95% 0.97-4.38) ] and extension of 
CAL > 3 mm  [ OR 1.78 (CI95% 1.16-1.71) vs.  1.37 (CI95% 0.89-2.11)]. When the two tests were evaluated together 
were not shown to be better than serum cotinine test.
Conclusions: Self-reported smoking and serum cotinine test ≥ 10ng/ml are accurate ,complementary  and more 
reliable methods to assess the patient’s smoking status and could be used in studies evaluating serum samples in 
large population and multicenter studies.
Clinical Relevance: The serum cotinine level is more reliable to make associations with the patient’s periodontal 
status than self-report questionnaire and could be used in multicenter and periodontal medicine studies. 
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Introduction
Smoking is a chronic habit that causes dependence. The 
World Health Organization (WHO) currently estimates 
that each year smoking accounts for about ~6 million 
deaths worldwide, being the first unnatural cause of 
death that is associated with several diseases like ag-
gravated cardiovascular disease and obstructive pulmo-
nary deficiency in developed and developing countries 
(1). Additionally, smoking is considered one of the main 
risk factors in periodontitis; smokers had greater chanc-
es for more severe alveolar bone loss compared to non-
smokers and responded less favorably to non-surgical 
periodontal therapy (2-6).
The questionnaires for self-report used to assess smoking 
have the advantage of being reproducible methods, non-
invasive and low cost (7, 8). However, there are social fac-
tors related to the patient’s overall health that can lead to a 
denial of the habit to avoid being stigmatized or excluded 
from some services health (9,10). Cotinine has been widely 
used as a stable biomarker of tobacco exposure and has 
been used to correlate its levels with periodontal disease 
severity (11). Although saliva cotinine test has been widely 
used in association studies of smoking and periodontal dis-
ease, this sample is difficult to process in multicenter stud-
ies; recently also been reported the use of serum cotinine 
in studies of periodontal disease in large population sam-
ples. The Serum cotinine has a longer half life, it does not 
require adjusting hydration difference among individuals 
as in saliva test (12).  The saliva cotinine can be difficult to 
use in studies with large samples of population and multi-
center studies (13,14).
In the last decades, a large number of studies have been 
conducted to establish the association of periodontal 
disease and systemic diseases (15-17) and smoking is 
an important confounder in this association (18,19). In 
many studies, serum markers are the most important 
test to determine these relationships. Serum cotinine 
can be very useful in these studies to assess smoking 
status for control of this confounding factor (20). A 
smoker absorbs half a milligram of nicotine in each cig-
arette, which is degraded to cotinine (the major metabo-
lite close to nicotine), nicotine glucuronide, nircotrine 
and nornicotine primarily (21,22) .Nicotine possesses 
a very short half-life in the blood, approximately 2 h; 
in contrast, cotinine exhibits a longer serum half-life, 
approximately 19 h (23). However, serum cotinine may 
range from 10 to 20 ng / ml, and this variation is due 
to differences racial of the populations studied (24,25) 
.Thus determining the cutoff of cotinine in each study 
is important to estimate the accuracy of the surveys in 
detecting patients exposed vs. no exposed (26).
The aim of this study was to evaluate the accuracy of 
the cotinine serum test to evaluate the smoking habit 
and its value for detect association of smoking with se-
verity of periodontal disease.
Material and Methods
- Study population
The participants belonged to a multicenter study which 
evaluated genetic, microbiological and immunologi-
cal risk factors for periodontal disease and systemic 
inflammatory mediators and lipid profile. The partici-
pants were previously informed about its nature, and 
signed a written consent previously approved by the 
ethics committees of the participating institutions. A 
total of 578 patients over 35 years of age visiting the 
dental clinics of five dentistry faculties including: El 
Bosque University and Pontificia Javeriana University, 
(Bogotá, Colombia), CES University and Antioquia 
University (Medellin, Colombia) and Valle University 
(Cali, Colombia) participated in the study.  This report 
is part of a multicenter study of biological and microbio-
logical markers, so it was necessary to exclude patients 
who had taken antibiotics 45 days before the sampling. 
The use of mouthwashes was not considered because 
the sample was obtained in blood. Patients with auto-
immune diseases, diagnosed diabetes, taking Non-ste-
roidal anti-inflammatory drugs (NSAIAs), pregnant or 
nursing women, patients undergoing orthodontic treat-
ment and who have received periodontal treatment in 
the last year were excluded. 
- Clinical evaluation
Medical history and clinical examination were con-
ducted for each patient. Patients were examined by 
trained periodontists (AD, AG, CMA, SD). All clinical 
researchers underwent a calibration session on the di-
agnosis criteria. For the evaluation of all the risk fac-
tors of the study, CAL based case definition was used 
to determine the history of periodontal disease. Cali-
bration exercise yielded an agreement ≥ 82 % for CAL. 
Clinical attachment levels were obtained (Intra-class 
correlation coefficients ICC 0.82 to 0.90) and patients 
were classified according to the average of the clinical 
attachment loss (CAL) as follows: Control patients with 
different degrees of gingival inflammation with a mean 
of CAL <2 mm at the evaluated sites; mild-moderate 
CAL , patients having CAL with an average of 2-4 mm; 
and advanced with mean of CAL > 4 mm. The exten-
sion was classified into ranges of < or ≥ 50% of affected 
sites with CAL >3 mm in proximal sites, but it was used 
in other report of the study and not in the cotinine test 
report. Mean of pocket depth probing (PD), bleeding on 
probing (BOP) and dichotomic gingival index (GI) were 
obtained in all patients.
- Questionnaire (self-report)
Information regarding the patient’s tobacco smoke ex-
posure was initially collected through an interview. 
After one week, the smoking behavior was evaluated 
using a standard self-reported questionnaire. Smoking 
was established by any positive response by interview 
or self-reported questionnaire.
Med Oral Patol Oral Cir Bucal. 2017 Jul 1;22 (4):e425-31.                                                                                                              Cotinine test and self-reported smoking status 
e427
Sample collection and cotinine analysis: We used se-
rum samples to assemble a cohort of patients who un-
derwent a screening for systemic risk factor (biological 
markers). A blood sample was taken from each patient 
and serum was separated and stored at -20°C.  Cotinine 
concentrations from the serum samples were measured 
using a microplate EIA**, according to the manufac-
turer’s instructions. To determine the concentrations of 
cotinine, the results of absorbance were transformed to 
ng/ml using a linear regression model.
- Statistical analysis: The values of sensitivity, specificity, 
predictive values and likehood ratios were established for 
the cotinine cut-off values of 10, 15 and 20 ng/ml, taking 
self-reported smoking as the gold standard.  A  ROC curve 
was performed within the different cotinine cut-off values. 
The values of sensitivity, specificity, predictive values and 
likehood ratios for the survey were established taking the 
cotinine test cut-off value as the gold standard which showed 
the best accuracy. To establish the association between the 
smoking habit evaluated by the survey and the cotinine test 
with the periodontal status, a Chi-square test was performed 
with a 5% significance level (p < 0.05) and OR ( odds ratio) 
values were calculated adjusted to geographic region, age 
and sex by logistic regression analysis for midle-moderate 
CAL and advanced CAL. Another analysis was made to 
the extension of CAL. For all analysis the unadjusted and 
adjusted models were compared using the likelihood ratio 
chi-square (G2), Akaike’s Information Criterion (AIC), and 
the Bayesian Information Criterion (BIC).
Results 
A total of 578 patients (372 women and 206 men) were 
studied, 209 control, 191 mild/moderate and 178 ad-
vanced (Table 1). Table 2 shows the Comparison of 
Cotinine levels with periodontal clinic parameters in 
patients with serum cotinine ≥10 and ≤10. There was no 
statistically significant association between serum coti-
nine cut-off and bleeding on probing and gingival index. 
There was a statistically significant association between 
serum cotinine cut-off and the mean of CAL (p >0,004) 
and PD (p<0,0002). In the table 3 and 4 is presented 
a complete description for smokers assessed by self-
report and cotinine concentrations levels (10, 15 and 20 
ng/ml) , the sensitivity, specificity, predictive values and 
likelihood ratios for the different cotinine cut-off points 
of ≥ 5 ng/ml. (where self-reported smoking is the gold 
standard for this study).  Ten nanograms of cotinine/ml 
in the serum showed the highest sensitivity and nega-
tive predictive value to detect non-smokers. The ROC 
curve confirmed a cotinine level of ≥10 ng/ml efficient 
to detect smokers, (0.77 the value under a curve). In a 
cut-off of 5 ng/ml area which analyzes the sensitivity 
and specificity of the diagnostic test decreases accord-
ing to the ROC curve (0.76), for this reason analysis is 
not required below the cutoff of 10 ng / ml. A cotinine 
cut-off point ≥ 10 ng/ml detected the highest percentage 
of smoking patients. 118 participants (20.4%) referred 
being smokers in the self-report, while 127 participants 
(22%) were positive for the serum cotinine test at cut-
off point level 10 ng/ml. When both methods were com-
bined, i.e. a positive result for either the questionnaire or 
the serum cotinine test, identified 166 patients as smok-
ers (28.7%) (Table 5).
The table 6 shows a significant association between 
smoking and mild- moderate CAL when evaluated by 
cotinine levels ≥10 ng/ml (OR 2.03 (CI95% 1.16-3.53)) 
but these association was lost when was evaluated by 
either the survey (OR 1.08 (CI95% 0.62-1.87)). In se-
vere periodontitis serum cotinine test (≥10 ng/m) shows 
greater association (OR 2.36 (CI95% 1.30-4.31)) than 
PARAMeteR/DIAGnoSIS ContRoL PAtIentS MILD-MoDeRAte CAL ADvAnCeD CAL
                                                                               
Subjects
total     Percentage
209               36.1
total    Percentage
191              33.0
total         Percentage
178               30.8
Gender
  F  148/209        39.7
  M   61/209        29.5
 F 125/191      33.5
 M 66/191       32.0
  F 99/178        26.5
  M 79/178       38.3
Age (Mean±SD) 45.6± 8.1b c  48.3±8.9a           48.6±10a
PD (Mean±SD) 2.1±0.4b,c 2.8±0.5a,c 4.1±0.9a,b
CAL(Mean±SD) 1.3±0.6b,c 2.8±0.6a,c 5.0±1.1a,b
Bleeding on probing (%±DS) 33±25b,c 56±26a,c 70±28a,b
Gingival index (%±DS) 39±30b,c 61±29aP 68±34a
table 1. Demographic characteristics of the population evaluated and clinical parameters of periodontal status.
CAL: Clinical attachment loss   PD: Pocket depth.
p<0.05 statistical test ANOVA, Kruskal Wallis, U Mann Whitney or Chi squared. 
a. Differences with Middle CAL, b. Differences with  Mild-Moderate CAL c. Differences with Advanced CAL.
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table 2  Comparison of Cotinine levels with periodontal clinic parameters.




    3.30
     3.18 (2.5 - 3.9)
        2.91




Plaque index  % 
Mean
Median (IQ range)
        
    3.46
   3.35 (2.4 - 4.6)
     60
  60 (38 – 90)
          
     2.87
     2.6 (1.7 – 3.95)
      56
    54 (32 – 82)
 0.0004
       
  0.12
Bleeding on probing 
Mean
Median IQ range
           
     55 
 54 (31 – 84)
        52




     
   56
59  (26 – 92)
      55
   59 (29 – 88)
  0.71
CAL: Clinical attachment loss   PD: Pocket depth; IQ range= Interquartile range; p<0.05 statistical U Mann Whit-
ney.
≥10 ng/ml ≥15 ng/ml ≥20 ng/mg








































table 3. Distribution of smokers and non-smokers determined self-reported smoking and serum cotinine test.
P+ Positive, N- negative.
Cl: confidence interval; PPV: positive predictive value; NPV:  negative predictive value; LR+: Positive likehood ratios; LR-: Negative likehood 
ratios.
Cutt-oFF
ng/ml SenSItIvIty SPeCIFICIty PPv nPv LR + LR -
 Cotinine 5
   CI 95%
   72.9
   63.9%     80.7%
     80.7%
   76.7%     84.2%
     49.1%   
    41.5%     56.8% 
92.1% 
89%     94.5%  
  3.77    
3.03- 4.68    
 0.3
0.2 - 0.4      
Cotinine 10 66.1% 89.3% 61.4% 91.1% 6.2 0.3
CI 95% 56.8% - 74.6% 86.2% - 92% 52.4% - 69.9% 88.1% - 93.6% 4.6 - 8.3 0.2- 0.4
Cotinine 15 51.7% 93% 65.6% 88.2% 7.4 0.5
CI 95% 42.3.% - 51% 90.3% - 95.2% 55%-71.2% 85% - 91% 5.1 – 10.8 0.4 - 0.6
Cotinine 20 50 % 94.1 % 68.6% 88% 8.5 0.5
CI 95% 40.7% - 51.3% 91.6% - 96.1% 57.7% -  78.2% 84.8% - 90.7% 5.6 – 12.8 0.4-0.6
table 4. Accuracy of serum cotinine cut-off points of 10 ng/ml aimed to detect smokers using data collected by survey as the gold standard.
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self-report questionnaire (OR 1.80 (CI95% 1.01-3.22)). 
When the two tests were evaluated together was not 
shown to be better than serum cotinine test (OR 1.76 CI 
95% 1.04-3.00)) for advanced CAL.
 
Discussion
Cotinine is the major metabolite of nicotine and the bio-
marker of choice because it is not influenced by diet or 
the environment surrounding the patients, thus fulfill-
ing requirements of specificity and half-life in the body 
(27). Levels from 10 to 20 ng/ ml due to variability in 
diverse racial groups (24,25), and uncut-off of 10ng/ml 
was the most sensitivity for detect smoking habit in the 
population evaluated in this study. 
The identification of environmental exposure to tobacco 
is difficult to determine through surveys. This is trou-
bling since there is evidence about the risk of periodon-
titis in passive smokers (13). Complement the smoking 
table 5.  Prevalence of smokers according to patient’s periodontal status evaluated by survey and/or 10 ng/ml serum co-
tinine levels
GRouPS
PoSItIve SMoKInG StAtuS AS DeteRMIneD By:
           SuRvey CotInIne           10  ng/mL
SuRvey + CotInIne
 10 ng/mL























CAL (Clinical Attachment Loss of full mouth) Control < 2mm, Mild-moderate CAL >2< 4 mm, Advanced CAL> 4 mm.
CI= Confidential interval.
Model 1: Comparison unadjusted OR and adjusted OR (adjusted to age, sex and region) Likehood ratio p=0.55. Difference 
in BIC and AIC criteria provides positive support for the unadjusted OR.
Model 2: Comparison unadjusted OR and adjusted OR (adjusted to age, sex and region) Likehood ratio p=0.59 Difference 
in BIC and AIC criteria provides positive support for the unadjusted OR.
Model 3: Comparison unadjusted OR and adjusted OR (adjusted to age, sex and region) Likehood ratio p=0.88. Difference 
in BIC and AIC criteria provides positive support for the unadjusted OR.
     unadjusted      Adjusted
Dependent variables Independent variables  oR     CI   95%    oR    CI  95% 
 Model 1 
Cotinine (10ng/ml)       
CAL  < 2 mm 1    1
CAL   2-4 mm
CAL   >4 mm
 2.03   1.16-3.53
 2.36   1.30-431
   1.93    1.09-3.43
   2.06    0.97-4.38
Model 2
Survey
CAL < 2 mm
CAL 2 -4 mm
   1
 1.08    0.62-1.87
   1
   1.14    0.63-204
CAL > 4 mm  1.80    1.01-3.22    2.06    0.97-4.38
Model 3        
Survey + Cotinine CAL < 2 mmCAL 2-4 mm
     1
 1.46     0.90-2.36
     1
   1.45   0.88-2.40
CAL > 6mm  1.76     1.04- 3.0    1.74   0.89-3.04
table 6. Association of cigarette smoking with severity of clinical attachment loss evaluated by the test of cotinine, the 
survey and both methods.
Med Oral Patol Oral Cir Bucal. 2017 Jul 1;22 (4):e425-31.                                                                                                              Cotinine test and self-reported smoking status 
e430
habit survey with cotinine test could be useful to detect 
passive smokers or those who deny the habit. Serum 
cotinine test shows more association with periodontal 
status evaluated by clinical attachment level loss and 
pocket depth than smoking habit self-report question-
naires. This evidence seems to support the use of serum 
cotinine test in studies with a large population where 
serum samples are obtained. Serum cotinine had been 
utilized in epidemiologic studies in cardiovascular dis-
ease and other systemic diseases (28).
Although saliva cotinine test has been widely used in 
association studies of smoking and periodontal disease, 
this sample is difficult to process in multicenter studies; 
recently also been reported the use of serum cotinine 
in studies of periodontal disease in large population 
samples (29,30). 
Among current smokers, there was a dose-response 
relationship between cigarettes smoked per day and 
the odds of periodontitis (31). There is strong evidence 
that smokers have more CAL and periodontal pockets 
(32,33). These findings are in agreement with the results 
obtained in this study given that the patient’s smoking 
active status correlated with the severity of periodontal 
disease. There is strong evidence of the association of 
smoking and severe periodontitis evaluate by CAL and 
PD; Current smoking is a significant predictor of clini-
cal attachment loss in longitudinal studies. However, 
in this study the association between smoking evalu-
ate by cotinine with bleeding on probing and gingival 
index were not significant; others studies had shown 
that smoking exerts a dose-dependent suppressive ef-
fect on gingival bleeding on probing (34). A hypothesis 
about these findings is that there were positive patients 
to cotinine but they were passive smokers. In addition 
the cut-off point of 10 ng/ml may not be determinant to 
demonstrate changes in the BOP.
In general, both the smoking survey and the serum co-
tinine tests independently showed associations with the 
presence and severity of periodontal disease. This study 
also explored the association between the primary study 
variable (CAL based case definition) and the severity of 
periodontitis. Cotinine levels at a cut-off of 10 showed 
a greater association with the severity of the periodon-
tal disease evaluated by CAL. Cotinine test may be 
influenced by the time between the last exposure and 
sampling of blood (35). In this study 35% of patients 
surveyed reported smoking test were negative in coti-
nine; 75% smoked less than 10 cigarettes per day and 
40% showed levels <10 ng / ml of cotinine in serum 
(data not shown). People that do not smoke frequently 
and occasional smokers could have negative test since 
cotinine is not detected 30 hours after smoking cessa-
tion (36). Although serum cotinine test did not identify 
some patients at the cutoff point of 10 ng/ml, it was 
more sensible to establish associations with periodon-
tal status possibly because identify patients with more 
active habit. Interestingly, 13.1% of the patients who 
reported non-smoke in the survey were positive in the 
serum cut-off point of 10 ng/ ml cotinine test; patients 
in the questionnaires can hide or lie about smoking by 
social fears. 
The serum cotinine test has limitations such as the im-
possibility to determine the time of smoking exposure, 
number of cigarettes smoked per day, and both methods 
can be complementary in the evaluation of smoking habit 
when these variables are relevant in the study.
Conclusions
Self-reported smoking and serum cotinine test ≥ 10ng/
ml are accurate and complementary methods to assess 
the patient’s smoking status. The cotinine level is more 
reliable to make associations with the patient’s peri-
odontal status. Serum cotinine could be used in stud-
ies evaluating serum samples in large population and 
multicenter studies.
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